Effect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes
AM Patti, RV Giglio, A Allotta, A Bruno, T Di Bella… - Biomedicines, 2023 - mdpi.com
Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist.
Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) …
Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) …
Effect of oral semaglutide on cardiovascular parameters and their mechanisms in patients with type 2 diabetes: Rationale and design of the Semaglutide Anti …
M Janić, M Rizzo, F Cosentino, A Pantea Stoian… - Diabetes Therapy, 2022 - Springer
Abstract Introduction Type 2 diabetes (T2D) management has reached a point where not
only optimal glycaemic control is necessary, but also additional interventions with proven …
only optimal glycaemic control is necessary, but also additional interventions with proven …
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
JFK Saraiva, D Franco - Cardiovascular Diabetology, 2021 - Springer
Cardiovascular events related to atherosclerosis are responsible for high morbidity and
mortality among patients with type 2 diabetes. Improvement in care, especially in early …
mortality among patients with type 2 diabetes. Improvement in care, especially in early …
Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis
AS Cleto, JM Schirlo, M Beltrame… - International Journal of …, 2024 - nature.com
Background Semaglutide is a GLP-1 receptor agonist that provides a reduction in glycated
hemoglobin and weight. The objective was to evaluate whether the use of semaglutide, in …
hemoglobin and weight. The objective was to evaluate whether the use of semaglutide, in …
Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials
LG Mellbin, DL Bhatt, JP David, K Ekström… - European Heart …, 2024 - academic.oup.com
Methods Data were pooled for participants with type 2 diabetes and established CV disease
or high CV risk in the SUSTAIN 6 and PIONEER 6 trials. Participants received sc …
or high CV risk in the SUSTAIN 6 and PIONEER 6 trials. Participants received sc …
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
M Husain, A Consoli, A De Remigis… - Cardiovascular …, 2022 - Springer
Abstract Background Cardiovascular outcome trials (CVOTs) are conducted on a
background of standard of care including metformin. These analyses sought to determine …
background of standard of care including metformin. These analyses sought to determine …
Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes: rationale and design of the semaglutide treatment on coronary …
Background: Cardiovascular morbidity and mortality are a major burden in patients with type
2 diabetic mellitus. In a landmark study, semaglutide (an injectable glucagon like peptide-1 …
2 diabetic mellitus. In a landmark study, semaglutide (an injectable glucagon like peptide-1 …
Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2
diabetes (T2D) available in subcutaneous (sc) and oral formulations. Two cardiovascular …
diabetes (T2D) available in subcutaneous (sc) and oral formulations. Two cardiovascular …
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
MN Kosiborod, M Bhatta, M Davies… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic …
DK McGuire, RP Busui, J Deanfield… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To describe the design of the SOUL trial (Semaglutide cardiOvascular oUtcomes triaL)
and the baseline clinical data of its participants. Materials and methods In SOUL, the effects …
and the baseline clinical data of its participants. Materials and methods In SOUL, the effects …